Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
Biogen posts Q2 2026 results, sets five late-stage readouts over next four quartersJul 29Quarterly updateBiogenfelzartamab